Table 5

Demographic and clinical characteristics of ET patients

JAK2 V617F negative

JAK2 V617F positive


GCC genotype

GCC genotype

P value

No (n = 19)

Yes (n = 23)

No (n = 22)

Yes (n = 35)


Age, mean (SD)

51.2 (18.3)

57.9 (17.5)

64.8 (14.9)

66.1 (16.2)

0.6466

Sex

Female

10 (52.6%)

14 (60.9%)

8 (36.4%)

22 (62.9%)

0.2965

Male

9 (47.4%)

9 (30.1%)

14 (64.6%)

13 (37.1%)

Splenomegaly

11/16 (68.8%)

4/22 (18.2%)

5/20 (25%)

4/33 (12.1%)

0.0448*

Thrombosis

0/11 (0%)

5/21 (23.8%)

6/17 (35.3%)

7/30 (23.3%)

0.0446*

Therapy requirement

10/16 (90%)

15/22 (68.2%)

7/21 (33.3%)

25/34 (73.5%)

0.7408

Cytogenetic abnormality

1/8(0%)

0/16 (0%)

2/9 (22.2%)

4/21(19%)

0.3618

MF evolution

0/16 (0%)

1/22 (4.5%)

0/15 (0%)

1/30 (3.3%)

0.3787

AML evolution

0/11 (0%)

1/22 (4.5%)

0/15 (0%)

0/30 (0%)

0.7343

Survival, mean (SD)

2036 (2267)

1883 (1643)

1706 (1847)

1717 (292)

0.6528


Statistical analysis was done among four groups.

P value is obtained from multivariate analysis.

Asterisks indicate statistically significant values.

Ohyashiki et al. BMC Medical Genetics 2012 13:6   doi:10.1186/1471-2350-13-6

Open Data